Table 1

Characteristics of samples used in this study grouped by responses of cells to Tipifarnib and GO: bulk cells
AML# Cytogenetics FLT3 Status NPM1 Status CD33 MFI Pgp status Tip%cell loss1 GO%cell loss1 Tip/GO%cell loss1 Δtox2
#19 normal WT WT 1.7 NEG 33 70 85 -
#1 normal ITD MUT 74 NEG 60 23 82 −1
#10 plus 8 ITD WT 3.7 NEG 54 3 75 18
#17 inv(16) ITD WT 22 NEG 35 27 75 13
#13 normal WT WT NEG 42 39 74 −7
#3 inv(16) WT WT 19 POS 36 0 70 34
#15 ITD WT 3.3 POS 50 17 69 2
#27 complex ITD WT 38 NEG 0 0 68 68
#33 del(13) ITD 198 NEG 38 19 65 8
#14 normal ITD MUT 8.7 NEG 43 4 65 18
#32 ITD MUT 46 NEG 19 18 65 28
#8 normal WT MUT 83 NEG 20 12 63 31
#12 inv(16) WT WT 1.5 NEG 56 28 63 −21
#26 ITD MUT NEG 22 31 58 5
#11 ITD MUT 43 NEG 11 1 55 43
#30 WT WT 38 NEG 29 18 54 7
#34 normal ITD MUT 1.3 NEG 4 42 52 6
#20 WT WT 30 POS 27 23 50 0
#21 del(5q) ITD MUT 59 NEG 40 25 49 −16
#5 normal ITD MUT 75 NEG 0 16 46 30
#25 dup1, add12, add16 WT 36 POS 18 10 43 15
#9 normal ITD MUT 8.4 NEG 19 19 42 4
#6 normal ITD MUT 0.19 NEG 31 37 41 −27
#16 51 21 21 40 −2
#4 ITD MUT 89 NEG 33 0 35 2
#35 complex WT WT 18.2 POS 14 5 21 2
#31 normal ITD WT 11 POS 7 0 20 13
#2 WT WT 3.4 POS 2 0 17 15
#7 plus 11 WT WT 23 NEG 0 3 15 12
#29 normal WT MUT 140 NEG 16 0 14 −2
#28 complex 4.9 POS 0 2 2 0
#18 −5 WT WT 2.1 POS 0 8 0 −8
#36 WT WT 6.3 9 2 0 −11
#23 WT WT 36 0 1 0 −1

34 AML samples used in this study ordered by magnitude of response to tipifarnib + GO (column second from the right).

1% of cells lost after 48 hours treatment (compared to untreated control).

2 Δtox = cell loss with drug combination – (cell loss with tipifarnib + cell loss with GO). No values are displayed when cell loss with tipifarnib + cell loss with GO= > 100%.

Jawad et al.

Jawad et al. BMC Cancer 2012 12:431   doi:10.1186/1471-2407-12-431

Open Data